Middle East And Africa Point Care Testing Poct Market
Marktgröße in Milliarden USD
CAGR :
% 
USD
3.15 Billion
USD
7.11 Billion
2025
2033
 Prognosezeitraum |
2026 –2033 |
 Marktgröße (Basisjahr) | USD 3.15 Billion |
 Marktgröße (Prognosejahr) | USD 7.11 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
|
Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika, nach Produkttyp (Glukoseüberwachungsprodukte, Produkte für Tests auf Infektionskrankheiten, Produkte zur kardiometabolischen Überwachung, Produkte für Schwangerschafts- und Fruchtbarkeitstests, Produkte für Hämatologietests, Produkte zur Gerinnungsüberwachung, Produkte für Drogenmissbrauchstests (DOA), Produkte für Urinanalysetests, Produkte für Cholesterintests, Produkte für Tests auf Tumor-/Krebsmarker, Produkte für Tests auf okkultes Stuhl und andere), nach Plattform (Lateral-Flow-Assays/Immunchromatographie-Tests, Immunoassays, Teststreifen, Molekulardiagnostik, klinisch-chemische Assays, Mikrofluidik, Hämatologie und andere), nach Anwendung (Blutzucker, Infektionskrankheiten, Überwachung der Vitalfunktionen, Herzüberwachung, Gerinnung, Hämatologie, nicht-invasive SpO2-Überwachung, Bluttransfusion, nicht-invasive PCO2-Überwachung, Vollblutanalyse und andere), nach Verschreibungsmodus (Verschreibungspflichtige Tests und über die Thekentests, nach Endbenutzer (Krankenhäuser, häusliche Pflege, Kliniken, Labore, Diagnosezentren, Pathologielabore, ambulante Operationszentren, Altenpflegezentren, andere), nach Vertriebskanal (Direktausschreibung, Einzelhandelsverkauf, Online-Verkauf und andere) – Branchentrends und Prognose bis 2032
Marktanalyse für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
Der Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika verzeichnet aufgrund medizintechnischer Fortschritte, der steigenden Nachfrage nach Schnelldiagnostik und der Zunahme chronischer Erkrankungen ein starkes Wachstum. PoCT ermöglicht schnelle Ergebnisse direkt beim Patienten, verbessert die Behandlungsergebnisse und senkt die Gesundheitskosten. Wichtige Treiber sind der zunehmende Fokus auf personalisierte Medizin, die alternde Bevölkerung und die bequeme Durchführung von Heimtests. Darüber hinaus prägen Innovationen im Bereich der mobilen Gesundheit (mHealth) und tragbarer Geräte den Markt. Nordamerika hält den größten Marktanteil, während im asiatisch-pazifischen Raum aufgrund der steigenden Gesundheitsinfrastruktur und Nachfrage das schnellste Wachstum erwartet wird.
Marktgröße für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
Der Markt für Point-of-Care-Tests (POCT) im Nahen Osten und in Afrika hatte im Jahr 2024 einen Wert von 2,01 Milliarden US-Dollar und soll bis 2032 4,51 Milliarden US-Dollar erreichen, mit einer CAGR von 10,7 % im Prognosezeitraum 2025 bis 2032. Zusätzlich zu den Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und wichtige Akteure enthalten die von Data Bridge Market Research kuratierten Marktberichte auch Import-Export-Analysen, eine Übersicht über die Produktionskapazität, eine Analyse des Produktionsverbrauchs, eine Preistrendanalyse, ein Szenario des Klimawandels, eine Lieferkettenanalyse, eine Wertschöpfungskettenanalyse, eine Übersicht über Rohstoffe/Verbrauchsmaterialien, Kriterien für die Lieferantenauswahl, eine PESTLE-Analyse, eine Porter-Analyse und regulatorische Rahmenbedingungen.
Markttrends für Point-of-Care-Tests (POCT) im Nahen Osten und in Afrika
„Steigende Einführung fortschrittlicher Diagnosetechnologien im Nahen Osten und in Afrika – Point-of-Care-Tests (POCT)“
Der Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika verzeichnet ein starkes Wachstum, angetrieben durch Fortschritte in der Diagnosetechnologie, die steigende Nachfrage nach Schnelltests und den anhaltenden Bedarf an zugänglichen Gesundheitslösungen. Zu den wichtigsten Trends zählt der Aufstieg dezentraler Gesundheitssysteme, bei denen Tests von zentralen Laboren in patientennahe Umgebungen wie zu Hause, in Apotheken und Kliniken verlagert werden. Die zunehmende Verbreitung mobiler Gesundheitsgeräte und Wearables ermöglicht Echtzeitüberwachung und sofortige Diagnoseergebnisse. Darüber hinaus verbessern Innovationen bei molekularen und genetischen Tests die Genauigkeit und erweitern den Anwendungsbereich von POCT auf ein breiteres Spektrum von Erkrankungen, von Infektionskrankheiten bis hin zu chronischen Krankheiten. Regulatorische Unterstützung und günstige Erstattungsrichtlinien fördern das Marktwachstum zusätzlich. Die COVID-19-Pandemie hat zudem den Einsatz von POCT zur schnellen Erkennung von Virusinfektionen beschleunigt und seine Rolle im öffentlichen Gesundheitsmanagement gefestigt. Da die Nachfrage nach schnelleren und komfortableren Diagnoseinstrumenten steigt, wird erwartet, dass der POCT-Markt seinen Aufwärtstrend fortsetzt, wobei der Fokus auf Erschwinglichkeit, Benutzerfreundlichkeit und der Integration in digitale Gesundheitsplattformen liegt.
Berichtsumfang und Marktsegmentierung für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
|
Eigenschaften |
Markteinblicke für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika |
|
Abgedeckte Segmente |
|
|
Abgedeckte Region |
Südafrika, Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Kuwait, Israel, Katar, Oman, Bahrain und der Rest des Nahen Ostens und Afrikas |
|
Wichtige Marktteilnehmer |
F. Hoffmann-La Roche Ltd (Schweiz), Danaher Corporation (USA), Siemens Healthineers AG (Deutschland), BD (Becton, Dickinson and Company) (USA), Abbott (USA), Pfizer Inc. (USA), QuantuMDx Group Ltd. (Großbritannien), Thermo Fisher Scientific Inc. (USA), Nova Biomedical (USA), Trividia Health, Inc. (USA), Sienco, Inc. (USA), PTS Diagnostics (USA), Abaxis (ein Teil von Zoetis) (USA), Werfen (Spanien), Binx Health (USA), BIOMÉRIEUX (Frankreich), QIAGEN (Deutschland), QuidelOrtho Corporation (USA), Accubiotech Co., Ltd. (China), Sekisui Diagnostics (USA), Trinity Biotech (Irland), BD Veritor (BD) (USA), Hologic, Inc. (USA), Sysmex Corporation (Japan) und Meridian Bioscience (USA) |
|
Marktchancen |
|
|
Wertschöpfungsdaten-Infosets |
Zusätzlich zu den Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und wichtige Akteure enthalten die von Data Bridge Market Research kuratierten Marktberichte auch Import-Export-Analysen, eine Übersicht über die Produktionskapazität, eine Analyse des Produktionsverbrauchs, eine Preistrendanalyse, ein Szenario des Klimawandels, eine Lieferkettenanalyse, eine Wertschöpfungskettenanalyse, eine Übersicht über Rohstoffe/Verbrauchsmaterialien, Kriterien für die Lieferantenauswahl, eine PESTLE-Analyse, eine Porter-Analyse und regulatorische Rahmenbedingungen. |
Marktdefinition für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
Der Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika umfasst diagnostische Tests, die direkt am Patientenversorgungsort, z. B. zu Hause, in Kliniken, Apotheken oder Krankenhäusern, durchgeführt werden und schnelle und präzise Ergebnisse liefern. POCT umfasst Geräte zur Untersuchung einer Vielzahl von Erkrankungen, von Infektionskrankheiten bis hin zu chronischen Leiden wie Diabetes und Herzerkrankungen. Der Markt wird durch technologische Fortschritte vorangetrieben, darunter tragbare Geräte, mobile Gesundheitslösungen und Wearables, die Echtzeitdiagnostik ermöglichen. Die wachsende Nachfrage nach komfortabler und kostengünstiger Gesundheitsversorgung, insbesondere in dezentralen Einrichtungen, sowie unterstützende regulatorische Rahmenbedingungen treiben das Wachstum des POCT-Marktes im Nahen Osten und Afrika voran.
Marktdynamik für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
Treiber
- Zunehmender Einsatz von POC-Tests in Gesundheitseinrichtungen
Der zunehmende Einsatz von Point-of-Care-Tests (POC) in Gesundheitseinrichtungen revolutioniert die Art und Weise, wie Gesundheitsdienstleister Krankheiten diagnostizieren und behandeln. Angesichts des steigenden Bedarfs an schnellen und präzisen Diagnoseergebnissen setzen medizinische Fachkräfte verstärkt auf POC-Tests, um die Patientenversorgung zu verbessern. Dieser Wandel zeigt sich insbesondere in Notaufnahmen, Ambulanzen und Diagnosezentren, wo schnelle Entscheidungen entscheidend sind. POC-Tests ermöglichen es Gesundheitsdienstleistern, unmittelbar Ergebnisse am Point-of-Care zu erhalten. Patienten müssen nicht mehr auf Laborergebnisse warten, was die Zeit bis zur Diagnose und Behandlung deutlich verkürzt. Darüber hinaus sind POC-Tests leicht transportabel und benutzerfreundlich und eignen sich daher ideal für den Einsatz in verschiedenen Gesundheitseinrichtungen, von ländlichen Kliniken bis hin zu großen Krankenhäusern. Die zunehmende Verbreitung chronischer Krankheiten und die wachsende Nachfrage nach effizienten Gesundheitslösungen fördern die Einführung von POC-Tests zusätzlich, da sie eine bessere Krankheitsüberwachung ermöglichen, insbesondere bei Erkrankungen wie Diabetes, Herz-Kreislauf-Erkrankungen und Infektionskrankheiten. Da Gesundheitseinrichtungen diese Technologien zunehmend in ihre Arbeitsabläufe integrieren, steigt die Nachfrage nach Point-of-Care-Tests weiter und ist ein wichtiger Treiber für das Marktwachstum.
Zum Beispiel,
- Laut einem im März 2024 veröffentlichten Artikel des NCBI verbessert die schnelle Durchlaufzeit von POCT die klinische Entscheidungsfindung, verkürzt den Behandlungsaufwand und verbessert die Triage-Effizienz, insbesondere in Notaufnahmen. Die Flexibilität erstreckt sich auch auf präklinische Situationen, Feldlazarette sowie bei Katastrophen, Massenveranstaltungen oder in überfüllten Gebieten. Die breite Einführung von POCT in Gesundheitseinrichtungen beschleunigt die Nachfrage und ist ein wichtiger Treiber für den Markt im Nahen Osten und Afrika.
- Laut einem im November 2024 von OBJECTIVE Investment Banking & Valuation veröffentlichten Artikel revolutionierte die Umstellung auf Point-of-Care-Tests (POCT) das Gesundheitswesen, indem sie die Diagnostik direkt an den Ort der Patientenversorgung brachte. Ihre Geschwindigkeit, ihr Komfort und ihre Effizienz machen sie in Notfällen, ambulanten Behandlungen und in abgelegenen Einrichtungen unverzichtbar. Mit der steigenden Nachfrage nach Schnelldiagnostik treibt die Integration von POCT in die klinische Praxis das Marktwachstum voran und wirkt als wichtiger Katalysator für das Marktwachstum im Nahen Osten und Afrika.
- Die zunehmende Nutzung von Point-of-Care-Tests (POC) in Gesundheitseinrichtungen verändert die Diagnose und Behandlung von Krankheiten. Da schnelle und präzise Ergebnisse erforderlich sind, nutzen Gesundheitsdienstleister POC-Tests, um die Patientenversorgung zu verbessern. Dies ist besonders wichtig in Notaufnahmen, Ambulanzen und Diagnosezentren, wo zeitnahe Entscheidungen entscheidend sind. POC-Tests liefern sofortige Ergebnisse, verkürzen die Wartezeiten auf Laborberichte und beschleunigen Diagnose und Behandlung. Dank ihrer Mobilität und Benutzerfreundlichkeit eignen sie sich für verschiedene Gesundheitsumgebungen, von ländlichen Kliniken bis hin zu großen Krankenhäusern. Die steigende Prävalenz chronischer Erkrankungen wie Diabetes und Herz-Kreislauf-Erkrankungen sowie die Nachfrage nach effizienten Gesundheitslösungen treiben den Einsatz von POC-Tests weiter voran und fördern ein besseres Krankheitsmanagement und Marktwachstum.
Steigende Zahl von Drogenmissbrauch
Der weltweit steigende Drogenmissbrauch hat maßgeblich zum Wachstum des Marktes für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika beigetragen. Angesichts der steigenden Zahl von Menschen mit Substanzgebrauchsstörungen besteht ein dringender Bedarf an schnellen und zuverlässigen Diagnoseinstrumenten, die Substanzmissbrauch rasch erkennen und die Wirksamkeit der Behandlung überwachen können. POCT bietet den Vorteil, sofortige Ergebnisse zu liefern, was für ein rechtzeitiges Eingreifen, insbesondere in Notsituationen oder bei dringender Behandlung, entscheidend ist. Diese Testmethode ermöglicht es medizinischem Fachpersonal, Substanzen wie Alkohol, Opioide und illegale Drogen in Echtzeit zu erkennen und so effizientere Entscheidungsfindung und Behandlungsstrategien zu ermöglichen. Mit dem wachsenden Bewusstsein für Drogenmissbrauch steigt zudem die Nachfrage nach zugänglichen und erschwinglichen Testlösungen in verschiedenen Gesundheitseinrichtungen wie Kliniken, Suchtbehandlungszentren und Rehabilitationseinrichtungen weiter an. Angesichts der zunehmenden staatlichen und öffentlichen Gesundheitsinitiativen zur Bekämpfung des Drogenmissbrauchs spielt POCT eine entscheidende Rolle bei der Bewältigung der Krise, fördert seine breite Akzeptanz und das Marktwachstum.
Zum Beispiel,
- Laut einem NCBI-Artikel waren im Januar 2024 weltweit über 16 Millionen Menschen von Opioidkonsumstörungen betroffen, darunter 2,1 Millionen in den USA. Im Nahen Osten und Afrika führt dies jährlich zu über 120.000 Todesfällen. Opioidkonsum und -abhängigkeit sind weit verbreitet; bis zu 50 % der Langzeit-Opioidkonsumenten erfüllen die Kriterien für Opioidkonsumstörungen. Die steigende Zahl opioidbedingter Probleme erfordert effektive Drogentestlösungen und treibt damit das Wachstum des Marktes für Point-of-CARE-Tests (POC) im Nahen Osten und Afrika voran.
- Laut einem im August 2023 veröffentlichten Artikel der WHO waren im Jahr 2019 im Nahen Osten und in Afrika etwa 600.000 Todesfälle auf Drogenkonsum zurückzuführen, davon etwa 80 % auf Opioide. Davon waren rund 125.000 auf eine Opioid-Überdosis zurückzuführen, während nicht tödliche Überdosierungen deutlich häufiger sind. Der Anstieg der Opioid-Überdosierungen wird auf die erhöhte Verfügbarkeit von Opioiden zur Behandlung chronischer Schmerzen und das Vorhandensein potenter Opioide auf dem illegalen Markt zurückgeführt. In den USA gab es im Jahr 2019 insgesamt 70.630 Todesfälle durch Drogenüberdosis, wobei in etwa der Hälfte dieser Fälle synthetische Opioide im Spiel waren. Von 2013 bis 2019 stieg die Sterberate durch synthetische Opioide in den USA um 1040 %, mit einem weiteren Anstieg während der COVID-19-Pandemie. Diese Daten unterstreichen die „steigende Zahl von Drogenmissbrauchsfällen“, indem sie die zunehmende Verbreitung und Schwere opioidbedingter Überdosierungen hervorheben, was die Nachfrage nach wirksamen Lösungen für Drogentests antreibt.
- Laut einem im Juni 2020 von ARCHIVERS of Pathology & Laboratory Medicine veröffentlichten Artikel hat die Opioid-Epidemie eine kritische Nachfrage nach Point-of-Care-Drogentests (POC) geschaffen, die erhebliche klinische Bedürfnisse decken. Während aktuelle POC-Tests Einschränkungen hinsichtlich Sensitivität und Spezifität aufweisen, zeichnen sich innovative Lösungen wie Mikrofluidik und Miniatur-Massenspektrometrie ab. Die zukünftige Entwicklung quantitativer POC-Geräte und Echtzeittests treibt die Nachfrage weiter an und ist ein wichtiger Treiber für das Marktwachstum im Bereich Drogenmissbrauch.
Der Anstieg des Substanzmissbrauchs im Nahen Osten und Afrika hat das Wachstum des Marktes für Point-of-Care-Tests (POCT) deutlich vorangetrieben. Mit der zunehmenden Verbreitung von Substanzgebrauchsstörungen steigt die Nachfrage nach schnellen und präzisen Diagnoseinstrumenten zur Erkennung und Überwachung von Substanzmissbrauch. POCT liefert sofortige Ergebnisse und ermöglicht so ein rechtzeitiges Eingreifen in Notsituationen und die Notfallversorgung. Es ermöglicht medizinischem Fachpersonal, Substanzen wie Alkohol, Opioide und illegale Drogen schnell zu identifizieren und so die Behandlung und Entscheidungsfindung zu verbessern. Mit zunehmendem Bewusstsein und verstärkten Bemühungen des öffentlichen Gesundheitswesens zur Bekämpfung von Substanzmissbrauch steigt die Nachfrage nach zugänglichen Testlösungen in Kliniken und Rehabilitationszentren weiter an und treibt die Einführung von POCT weiter voran.
- Zunehmende Nutzung der Telemedizin
Das rasante Wachstum der Telemedizin hat maßgeblich zum Aufstieg von Point-of-Care-Tests (POCT) beigetragen, insbesondere im Kontext der Telemedizin. Mit der Verbreitung von Telemedizinplattformen steigt die Nachfrage nach Diagnosetools, die es Gesundheitsdienstleistern ermöglichen, Patienten aus der Ferne zu überwachen, Untersuchungen durchzuführen und Ergebnisse in Echtzeit bereitzustellen. POCT-Lösungen spielen bei diesem Wandel eine entscheidende Rolle, da sie es medizinischem Fachpersonal ermöglichen, präzise und zeitnahe Testergebnisse zu erhalten, ohne dass Patienten Kliniken oder Krankenhäuser aufsuchen müssen. Die Möglichkeit, Diagnostik zu Hause oder in abgelegenen Gebieten durchzuführen, verbessert nicht nur den Zugang der Patienten zur Gesundheitsversorgung, sondern steigert auch die Effizienz der Versorgung durch kürzere Wartezeiten und eine geringere Belastung der Gesundheitseinrichtungen. Die Integration von POCT in Telemedizinsysteme ermöglicht eine nahtlose Kommunikation zwischen Patienten und Gesundheitsdienstleistern und gewährleistet so zeitnahe Interventionen. Mit dem weiteren Wachstum der Telemedizin wird die Nachfrage nach POCT-Geräten, die für eine schnelle und zuverlässige Diagnostik in einer virtuellen Gesundheitsumgebung unerlässlich sind, zu einem wichtigen Treiber für das Marktwachstum.
Zum Beispiel,
- Laut einem im März 2024 von der DPU veröffentlichten Artikel ermöglicht Telemedizin die Fernversorgung, indem sie Patienten virtuell und ortsunabhängig mit medizinischem Fachpersonal verbindet. Bei Point-of-Care-Tests können Patienten Selbsttests durchführen oder sich vor Ort testen lassen, wobei die Ergebnisse zur Analyse an Spezialisten übermittelt werden. Dies ermöglicht zeitnahen Zugang zu medizinischer Beratung durch Experten, insbesondere in unterversorgten Gebieten, was den Bedarf an POCT-Lösungen steigert und das Marktwachstum ankurbelt.
- Laut einem im Februar 2022 veröffentlichten Artikel des Medical Device Network verändert die Point-of-Care-Diagnostik die Telemedizin, indem sie Patienten, insbesondere chronisch Kranken, einen einfacheren Zugang zu Diagnosedaten bietet. Dieser Wandel ermöglicht kontinuierliche Überwachung und zeitnahe Interventionen, selbst in Gebieten mit eingeschränkter Gesundheitsinfrastruktur. Mit der zunehmenden Verbreitung der Telemedizin steigt die Nachfrage nach effizienten und zugänglichen POCT-Lösungen und ist ein wichtiger Treiber für das Marktwachstum im Nahen Osten und Afrika.
Das rasante Wachstum der Telemedizin hat Point-of-Care-Tests (POCT) insbesondere in der Fernversorgung stark vorangetrieben. Mit der zunehmenden Verbreitung von Telemedizinplattformen steigt der Bedarf an Diagnosetools, die Fernüberwachung und Echtzeitergebnisse ermöglichen. POCT ermöglicht es Gesundheitsdienstleistern, präzise Testergebnisse zu erhalten, ohne dass Patientenbesuche erforderlich sind. Dies verbessert den Zugang zur Versorgung und verkürzt Wartezeiten. Durch die Integration von POCT in die Telemedizin wird die Kommunikation zwischen Patienten und Anbietern optimiert und zeitnahe Interventionen gewährleistet. Mit der Weiterentwicklung der Telemedizin treibt die Nachfrage nach POCT-Geräten das Marktwachstum weiter voran.
Gelegenheiten
- Steigendes Bewusstsein und Befürwortung von Point-of-Care-Tests
Das zunehmende Bewusstsein für die Bedeutung einer Frühdiagnose, gepaart mit intensiven Gesundheitskampagnen und staatlicher Unterstützung, bietet erhebliche Wachstumschancen für den Markt für Point-of-Care-Tests (POC) im Nahen Osten und Afrika. Da die Gesellschaft zunehmend auf eine proaktive Gesundheitsversorgung setzt, steigt die Nachfrage nach zugänglichen und effizienten Testlösungen. Gesundheitskampagnen staatlicher und nichtstaatlicher Organisationen spielen eine entscheidende Rolle bei der Aufklärung der Bevölkerung über die Vorteile einer Früherkennung und rechtzeitigen Intervention. Diese Initiativen schärfen nicht nur das Bewusstsein für verschiedene Gesundheitsprobleme, sondern setzen sich auch für den breiten Einsatz von Point-of-Care-Tests zur Verbesserung der Patientenergebnisse ein. Staatliche Förderung durch Finanzierung und Politikgestaltung erleichtert zudem die Einführung von POC-Testtechnologien durch die Schaffung günstiger regulatorischer Rahmenbedingungen. Dies fördert die Implementierung dieser Lösungen in verschiedenen Umgebungen, wie z. B. in Kliniken, Krankenhäusern und sogar in abgelegenen oder unterversorgten Gebieten. Die Kombination aus gesteigertem Bewusstsein und strategischer staatlicher Unterstützung schafft ein günstiges Umfeld für Marktexpansion, fördert Innovationen und erweitert den Zugang zu fortschrittlichen Testlösungen, um den wachsenden Gesundheitsbedarf im Nahen Osten und Afrika zu decken.
- Laut einem Artikel der Greater London Authority stellte die britische Regierung im Dezember 2023 1,54 Millionen US-Dollar für diese Mission bereit. Der Schwerpunkt liegt auf Tests auf 14 verschiedene Drogen. Das steigende Bewusstsein und proaktive Regierungsinitiativen in Großbritannien führten zur Einführung obligatorischer, stichprobenartiger Drogentests für aus dem Gefängnis entlassene Personen, um die Kriminalitätsrate zu senken. Dieser Schritt unterstreicht das Engagement des Landes im Kampf gegen Drogenmissbrauch und dessen Auswirkungen auf kriminelles Verhalten und spiegelt umfassendere Bemühungen zur Verbesserung der öffentlichen Sicherheit und des Wohlbefindens wider.
- Im Juli 2021 startete die australische Regierung laut einem vom Commonwealth of Australia und dem Ministerium für Gesundheit und Altenpflege veröffentlichten Artikel die Nationale Ice-Aktionsstrategie. Diese beinhaltete erhebliche Investitionen zur Verbesserung von Point-of-Care-Drogentests (POC). Ziel dieser Initiative war es, den zunehmenden Konsum von Methamphetaminen, allgemein bekannt als „Ice“, einzudämmen, indem Strafverfolgungsbehörden und Gesundheitsdienstleistern leichter zugängliche und präzisere Drogentestinstrumente zur Verfügung gestellt wurden. Die Strategie konzentrierte sich außerdem darauf, die Verfügbarkeit von POC-Tests in abgelegenen und ländlichen Gebieten zu erweitern, um sicherzustellen, dass Gemeinden im ganzen Land von zeitnahen und effektiven Maßnahmen zur Drogenerkennung und -intervention profitieren können.
Das Zusammenspiel aus steigendem Bewusstsein, proaktiven Kampagnen im Bereich der öffentlichen Gesundheit und starker staatlicher Unterstützung dürfte daher zu einem deutlichen Wachstum des Marktes für Point-of-Care-Tests (POC) im Nahen Osten und Afrika führen. Dieses dynamische Umfeld beschleunigt nicht nur die Einführung von POC-Testtechnologien, sondern fördert auch die Entwicklung fortschrittlicherer, effizienterer und zugänglicherer Lösungen. Angesichts dieser sich weiterentwickelnden Faktoren sieht die Zukunft der POC-Tests vielversprechend aus: mit verbesserten Innovationsmöglichkeiten, einer größeren Marktreichweite und verbesserten Gesundheitsergebnissen weltweit.
- Strategische Initiierung und Entscheidung der Marktteilnehmer
Strategische Kooperationen und Partnerschaften zwischen führenden Unternehmen und Forschungseinrichtungen treiben die Entwicklung fortschrittlicher Point-of-Care-Testtechnologien (POCT) voran und erweitern die Marktpräsenz. Diese Kooperationen ermöglichen es Unternehmen, ihr Produktangebot zu erweitern, die Genauigkeit zu verbessern und ihren Kundenstamm zu erweitern. Fusionen und Übernahmen stärken den Markt zusätzlich, indem sie komplementäre Technologien integrieren und neue Märkte erschließen. Die kontinuierliche Erweiterung des Produktportfolios und die Einführung innovativer Lösungen tragen den sich wandelnden Bedürfnissen von Branchen wie Gesundheitswesen, Bildung und Arbeitswelt Rechnung. Diese strategischen Anstrengungen fördern gemeinsam das Wachstum des POCT-Marktes und machen Tests im Nahen Osten und in Afrika zugänglicher, präziser und effizienter.
Zum Beispiel,
Im Februar 2021 übernahm Thermo Fisher Scientific laut einem Artikel von Thermo Fisher Scientific Inc. Mesa Biotech, ein auf molekulardiagnostische POC-Tests spezialisiertes Unternehmen. Während Mesa Biotech sich hauptsächlich auf Tests auf Infektionskrankheiten konzentrierte, verschaffte die Übernahme Thermo Fisher zusätzliche Kapazitäten im Bereich der POC-Schnelltests, die für die Expansion in den Bereich der Drogenmissbrauchstests genutzt werden könnten. Diese Übernahme ist Teil der umfassenderen Strategie von Thermo Fisher, sein POC-Testangebot in verschiedenen diagnostischen Bereichen zu erweitern.
Laut einem im Mai 2024 von ResearchGate veröffentlichten Artikel bietet die steigende Nachfrage nach schneller, präziser und zugänglicher Diagnostik eine bedeutende Chance für den Point-of-Care-Testing-Markt (POCT) im Nahen Osten und Afrika. Da Gesundheitssysteme nach effizienteren Alternativen zu herkömmlichen Labortests suchen, bietet POCT das Potenzial, die Patientenversorgung zu verbessern, indem es schnelle Ergebnisse ermöglicht, Wartezeiten verkürzt und Komfort bietet, insbesondere in abgelegenen oder ressourcenarmen Gebieten. Darüber hinaus können die Integration intelligenter Technologien und Fortschritte bei der Geräteempfindlichkeit Innovationen vorantreiben, die Testgenauigkeit verbessern und das Spektrum der diagnostizierbaren Erkrankungen erweitern. Zusammen schaffen diese Faktoren ein dynamisches Umfeld für Marktwachstum und die Entwicklung fortschrittlicherer, kostengünstigerer POCT-Lösungen.
- Laut einer im August 2022 in Healthcare Transformers veröffentlichten Meldung bietet POCT dem Gesundheitswesen im Nahen Osten und Afrika eine bedeutende Chance, da es die Zugänglichkeit insbesondere in unterversorgten Gebieten verbessert. Angesichts der steigenden Nachfrage nach schneller und kostengünstiger Diagnostik bieten mobile Einheiten und gemeindenahe Lösungen eine effiziente Versorgung. Das Potenzial von POCT, Gesundheitskosten zu senken, die Früherkennung von Krankheiten zu verbessern und die Krankenhausbelastung zu verringern, treibt Marktexpansion und Innovation voran.
Zusammenfassend lässt sich sagen, dass die strategischen Entscheidungen und Initiativen der wichtigsten Akteure entscheidend für das Wachstum der Point-of-Care-Testbranche sind. Unternehmen, die in Kooperationen, Fusionen und Portfolioerweiterungen investieren, profitieren von technologischen Fortschritten und einer höheren Produktverfügbarkeit. Diese Bemühungen werden der steigenden Nachfrage nach schneller und präziser Diagnostik gerecht, verbessern die Ergebnisse im Gesundheitswesen und unterstützen eine effizientere Patientenversorgung in verschiedenen Sektoren.
- Erweiterung der Produktpalette für Point-of-Care-Tests
Die wachsende Produktvielfalt für Point-of-Care-Drogentests (POC) bietet erhebliche Expansionsmöglichkeiten. Da der Bedarf an schnellen, präzisen und praktischen Drogentests steigt, erweitern Hersteller ihr Angebot um Teststreifen für einzelne Drogen, Kassetten für mehrere Drogen, Dip-Karten und Becher. Dieses vielfältige Produktangebot deckt unterschiedliche Testanforderungen ab – vom einfachen Screening zu Hause bis hin zu detaillierteren Multi-Drogen-Diagnostiken im klinischen und beruflichen Umfeld. Durch die Diversifizierung ihrer Produktlinien können Unternehmen ein breiteres Spektrum an Nutzerbedürfnissen abdecken, die Zugänglichkeit verbessern und unterschiedliche Komplexitäts- und Sensitivitätsstufen beim Drogennachweis berücksichtigen. Dieser Trend unterstützt nicht nur die steigende Nachfrage nach effizienten Drogentestlösungen, sondern fördert auch Innovation und Wettbewerb, was zu technologischem Fortschritt und verbesserter Testgenauigkeit und -zuverlässigkeit führt.
Zum Beispiel-
- Der im Januar 2025 veröffentlichte Artikel befasst sich laut ScienceDirect mit Fortschritten im Bereich der Point-of-Care-Diagnostik (POCT) und konzentriert sich dabei auf einstufige Lateral-Flow- und Mikrofluidik-Assays für die Heimdiagnostik. Wichtige Bereiche sind Signalverstärkung, Assay-Design und Probenvorbereitung, um den Benutzeraufwand zu reduzieren. Der Artikel betont die Bewältigung von Herausforderungen bei der Kommerzialisierung und die Gewährleistung kostengünstiger, zuverlässiger und zugänglicher Diagnoselösungen.
- Laut einer von Healgen veröffentlichten Studie verfügt das Unternehmen im Dezember 2023 über ein breites Produktsortiment, darunter Teststreifen, Kassetten und Dip-Karten für einzelne Drogen sowie Kassetten, Dip-Karten und Becher für mehrere Drogentests. Dieses umfangreiche Produktsortiment deckt verschiedene Testanforderungen und -situationen ab, von einfachen Tests für zu Hause bis hin zu umfassenderen Multi-Drogen-Screenings.
Die Erweiterung des Produktangebots im Markt für Point-of-Care-Tests (POC) im Nahen Osten und Afrika wird voraussichtlich zu deutlichem Wachstum und Innovation führen. Da sich der Markt weiterentwickelt, um den unterschiedlichen Nutzerbedürfnissen gerecht zu werden und technologische Fortschritte zu integrieren, wird ein breiteres Spektrum an Testlösungen die diagnostische Effizienz und Genauigkeit verbessern. Diese erhöhte Produktvielfalt (241 Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika – Branchentrends und Prognose bis 2032) wird voraussichtlich die Marktdurchdringung steigern, die Zugänglichkeit verbessern und umfassendere Testprogramme ermöglichen, was eine große Chance für die Marktexpansion darstellt.
Einschränkung/Herausforderung
- Begrenztes Bewusstsein und Akzeptanz
Mangelnde Bekanntheit und Akzeptanz von Point-of-Care (POC)-Tests können deren Marktwachstum und breite Anwendung erheblich behindern. Die langsame Akzeptanz bei Gesundheitsdienstleistern, Patienten und Kostenträgern erschwert die Nachfrage und den Absatz von POC-Geräten. Mangelnde Bekanntheit kann zu einer eingeschränkten Nutzung in den Bereichen des Gesundheitswesens führen, in denen diese Tests am dringendsten benötigt werden, was ihren Einfluss auf die Patientenversorgung und die Behandlungsergebnisse mindert. Ein weiteres Hindernis ist die fehlende Kostenerstattung. Eine geringe Akzeptanz kann zu reduzierten oder abgelehnten Kostenerstattungen führen und es Gesundheitsdienstleistern erschweren, diese Technologien zu finanzieren. Zudem kann fehlende Schulung und Ausbildung von Gesundheitsdienstleistern die korrekte Anwendung und Interpretation von POC-Testergebnissen beeinträchtigen und zu ungenauen Diagnosen führen.
Zum Beispiel,
- Der im Dezember 2024 in ScienceDirect veröffentlichte Artikel befasst sich mit den Herausforderungen und Vorteilen der Einführung von Point-of-Care-Tests (POCT) für Atemwegsinfektionen (RTI) in der Primärversorgung, insbesondere in Australien. Trotz technologischer Fortschritte ist die POCT-Einführung aufgrund von Faktoren wie Ressourcenverfügbarkeit, Schulung, Qualitätskontrolle und Patientenerwartungen nach wie vor gering. POCT kann jedoch den übermäßigen Einsatz antimikrobieller Mittel durch schnelle, evidenzbasierte Diagnosen deutlich reduzieren. Die Förderung einer breiteren Implementierung in der Primärversorgung ist entscheidend für die Verbesserung des Antibiotikamanagements und der Patientenergebnisse. Die Studie betont, wie wichtig es ist, zentrale Hindernisse zu beseitigen und Strategien zu entwickeln, um die breite Einführung von POCT im Management von RTI zu fördern.
- Laut dem im Juni 2024 in ResearchGate veröffentlichten Artikel bietet Point-of-Care-Testing (POCT) Vorteile wie Geschwindigkeit, Komfort und Kosteneinsparungen, birgt aber auch Herausforderungen wie geringere Genauigkeit, Qualitätskontrollprobleme, Bedienerabhängigkeit und regulatorische Bedenken. Da sich POCT hin zu dezentralen und direkt an den Verbraucher gerichteten Modellen entwickelt, sind sorgfältige Governance und Qualitätsbewertung notwendig, um zuverlässige klinische Entscheidungen zu gewährleisten.
Um diesen Herausforderungen zu begegnen, sollten Hersteller in gezielte Schulungs- und Trainingsprogramme für Gesundheitsdienstleister und Patienten investieren und dabei die Vorteile und die korrekte Anwendung von POC-Tests hervorheben. Solche Bemühungen tragen dazu bei, das Bewusstsein zu schärfen, die Akzeptanz zu verbessern und die allgemeine Effektivität von POC-Tests im Gesundheitswesen zu steigern, was letztlich zu besseren Patientenergebnissen führt.
- Hohe Wartungskosten gefährden die Nachhaltigkeit von Point-of-Care-Tests (POCT) in ressourcenarmen Umgebungen
Die hohen Wartungskosten stellen eine große Herausforderung im Point-of-Care-Testing (POCT)-Markt im Nahen Osten und Afrika dar. Regelmäßige Kalibrierung, Wartung und Instandhaltung von POCT-Geräten sind unerlässlich, um deren Genauigkeit, Zuverlässigkeit und Leistung dauerhaft zu gewährleisten. Diese Maßnahmen können jedoch erhebliche Kosten verursachen, insbesondere in ressourcenschwachen und budgetbeschränkten Gesundheitseinrichtungen. Viele POCT-Geräte benötigen regelmäßigen technischen Support, einschließlich des Austauschs verschlissener Komponenten, Software-Updates und der Sicherstellung der Einhaltung gesetzlicher Standards. All dies trägt zu den Gesamtbetriebskosten bei. Für Gesundheitsdienstleister in unterfinanzierten Regionen ist die Bereitstellung von Ressourcen für diese Wartung oft schwierig, was zu längeren Ausfallzeiten, erhöhten Betriebsrisiken und einer beeinträchtigten diagnostischen Genauigkeit führen kann. Darüber hinaus erfordert die Komplexität einiger POCT-Geräte spezialisierte Techniker für die ordnungsgemäße Wartung, was die Wartungskosten weiter in die Höhe treibt. Erschwerend kommt hinzu, dass das lokale Personal nicht ausreichend für grundlegende Wartungsaufgaben geschult ist, sodass die Einrichtungen auf kostspielige externe Unterstützung angewiesen sind. Infolgedessen verzögern oder verzichten viele Gesundheitsdienstleister auf notwendige Wartungsarbeiten, was die Gesamteffektivität und Lebensdauer der Geräte verkürzt.
Zum Beispiel,
- Laut einem im September 2020 in der National Library of Medicine veröffentlichten Artikel stellen die hohen Kosten für Point-of-Care-Tests (POCT) eine erhebliche Herausforderung für den Markt im Nahen Osten und Afrika dar. Anfängliche Investitionen in Ausrüstung, laufende Wartung und Schulung des Bedienpersonals können unerschwinglich sein, insbesondere in ressourcenarmen Umgebungen. Dies schränkt die breite Akzeptanz ein und beeinträchtigt die Kosteneffizienz, obwohl POCT das Potenzial hat, die Gesundheitsergebnisse zu verbessern.
- Im Mai 2023 wies das National Center for Biotechnology Information (NCBI) in einem Artikel der National Library of Medicine darauf hin, dass Point-of-Care-Testgeräte (POCT) zwar für eine schnelle Diagnostik nützlich sind, aber oft mit hohen Wartungskosten verbunden sind. Regelmäßige Kalibrierung und Wartung können die Ressourcen des Gesundheitswesens belasten, insbesondere in ressourcenarmen Umgebungen, was den nachhaltigen Einsatz dieser Technologien einschränkt.
Marktumfang für Point-of-Care-Tests (POCT) im Nahen Osten und in Afrika
Der Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika ist in sechs Segmente unterteilt, basierend auf Produkttyp, Verschreibungsart, Anwendung, Plattform, Endnutzer und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen, schwache Wachstumssegmente in den Branchen zu analysieren und bietet den Nutzern einen wertvollen Marktüberblick und Markteinblicke, die ihnen helfen, strategische Entscheidungen zur Identifizierung zentraler Marktanwendungen zu treffen.
Produkttyp
- Produkte zur Glukoseüberwachung
- Streifen
- Zähler
- Lanzetten und Stechhilfen
- Produkte zur Untersuchung von Infektionskrankheiten
- COVID-19
- HIV-Testprodukte
- Testreagenzien
- Prüfgeräte
- Produkte zur Prüfung auf Atemwegsinfektionen
- Tests auf sexuell übertragbare Krankheiten (STD)
- Naat-basierte Systeme
- Nicht-Naat-basierte Systeme
- Produkte zum Testen auf Hepatitis C
- HCV-Antikörpertests
- HCV-Viruslasttests
- Produkte für Grippetests
- Traditioneller Diagnosetest
- Schneller Grippe-Diagnosetest (Ridt)
- Direkter Fluoreszenz-Antikörpertest (Dfat)
- Virale Kultur
- Serologischer Test
- Traditioneller Diagnosetest
- Molekulardiagnostischer Test
- Rt-PCR
- Loop-vermittelter isothermer Amplifikations-basierter Test (Lampe)
- Nukleinsäuresequenzbasierter Amplifikationstest (Nasbat)
- Einfacher, auf Amplifikation basierender Test (Samba)
- Tests auf nosokomial bedingte Infektionen (HAI)
- Produkte zur Prüfung auf Tropenkrankheiten
- Andere Produkte zur Infektionskrankheitsprüfung
- Produkte zur kardiometabolischen Überwachung
- Produkte zur Untersuchung kardialer Marker
- Hstnl
- BNP
- D-Dimer
- Ck-Mb
- Myoglobin
- Produkte zur Untersuchung kardialer Marker
- Produkte zur Blutgas-/Elektrolytuntersuchung
- Verbrauchsmaterialien für Blutgas-/Elektrolyttests
- Patronen
- Reagenzien
- Instrumente zur Blutgas-/Elektrolyt-Testung
- Tragbar
- Kombinierte Analysatoren
- Blutgasanalysatoren
- Elektrolytanalysatoren
- Tischgerät
- Kombinierte Analysatoren
- Blutgasanalysatoren
- Elektrolytanalysatoren
- Tragbar
- Verbrauchsmaterialien für Blutgas-/Elektrolyttests
- Hba1c-Testprodukte
- Hba1c-Testgeräte
- Verbrauchsmaterialien für HbA1c-Tests
- PoC-Analysator
- EKG-Gerät
- Ruhe-EKG-Geräte
- Belastungs-EKG-Geräte
- Holter-Monitore
- Produkte für Schwangerschafts- und Fruchtbarkeitstests
- Produkte für Schwangerschaftstests
- Streifen/Teststreifen und Karten
- Midstream-Geräte
- Kassetten
- Digitale Geräte
- Leitungsanzeigegeräte
- Produkte für Fruchtbarkeitstests
- Luteinisierendes Hormon (LH) Urintest
- FSH-Test
- Sonstiges
- Produkte für Schwangerschaftstests
- Produkte für hämatologische Tests
- Produkte zur Gerinnungsüberwachung
- Geräte zur Überwachung der Antikoagulation
- Geräte zur Messung der Prothrombinzeit/International Normalized Ratio (Pt-Inr)
- Aktivierte Gerinnungszeit (Act)
- Aktivierte partielle Thromboplastinzeit (Appt)
- Geräte zur Überwachung der Thrombozytenfunktion
- Viskoelastische Gerinnungsüberwachungsgeräte
- Rotationsthromboelastometrie (Rotem)
- Thrombelastographie (Teg)
- Geräte zur Überwachung der Antikoagulation
- Produkte für Drogentests
- Doa-Analysatoren
- Immunassays
- Chromatographische Geräte
- Atemanalysegeräte
- Schnelltestgeräte
- Urintestgeräte
- Geräte zur Untersuchung von Mundflüssigkeit
- Sonstiges
- Doa-Analysatoren
- Produkte zur Urinanalyse
- Poc-Urinstreifen-Selbsttest
- Poc-Urinteststreifen Professionelle Tests
- Produkte zur Cholesterinbestimmung
- Testkits
- Instrumente
- Tischanalysatoren
- Tragbare Analysatoren
- Produkte zur Tumor-/Krebsmarker-Testung
- Produkte zum Testen von verborgenem Kot
- Guajak-Fob-Stuhltest
- Lateral Flow Immuno-Fob-Test
- Immuno-Fob-Agglutinationstest
- Immuno-Fob Elisa-Test
- Sonstiges
Plattform
- Lateral-Flow-Assays/Immunchromatographie-Tests
- Immunassays
- Ölmessstäbe
- Molekulare Diagnostik
- Klinisch-chemische Tests
- Mikrofluidik
- Hämatologie
- Sonstiges
Anwendung
- Blutzucker
- Infektionskrankheiten
- Covid-19-Tests
- HIV-Test
- Hepatitis-C-Test
- Grippetests
- Tuberkulose-Test
- Sonstiges
- Überwachung der Vitalfunktionen
- Herzüberwachung
- Gerinnung
- Hämatologie
- Nicht-invasive Spo2-Überwachung
- Bluttransfusion
- Nicht-invasive PCO2-Überwachung
- Vollblutanalyse
- Sonstiges
Rezeptmodus
- OTC-Tests
- Rezeptbasierte Tests
Endbenutzer
- Krankenhäuser
- Privat
- Stufe 1
- Stufe 2
- Stufe 3
- Öffentlich
- Stufe 1
- Stufe 2
- Stufe 3
- Privat
- Häusliche Pflege
- Kliniken
- Labore
- Diagnosezentren
- Pathologielabore
- Ambulante Operationszentren
- Altenpflegezentren
- Sonstiges
Vertriebskanal
- Direkte Ausschreibung
- Einzelhandelsumsätze
- Online-Verkäufe
- Sonstiges
Regionale Analyse des Point-of-Care-Testmarkts (POCT) im Nahen Osten und Afrika
Der Markt wird analysiert und es werden Einblicke in die Marktgröße und Trends basierend auf Land, Produkttyp, Verschreibungsmodus, Anwendung, Plattform, Endbenutzer und Vertriebskanal wie oben angegeben bereitgestellt.
Die vom Markt abgedeckten Länder sind Südafrika, Saudi-Arabien, die Vereinigten Arabischen Emirate, Ägypten, Kuwait, Israel, Katar, Oman, Bahrain und der Rest des Nahen Ostens und Afrikas.
Saudi-Arabien wird voraussichtlich den Point-of-Care-Testing-Markt (POCT) im Nahen Osten und Afrika dominieren. Grund dafür sind steigende Investitionen in die Gesundheitsinfrastruktur, die steigende Nachfrage nach schnellen Diagnoselösungen und die steigende Prävalenz chronischer Krankheiten. Staatliche Unterstützung und Initiativen zur Verbesserung des Zugangs und der Qualität der Gesundheitsversorgung fördern zudem die Einführung innovativer POCT-Technologien in der Region.
Südafrika dürfte im Prognosezeitraum der am schnellsten wachsende Point-of-Care-Testing-Markt (POCT) im Nahen Osten und in Afrika sein, und zwar aufgrund steigender Gesundheitsausgaben, einer zunehmenden Verbreitung von Infektionskrankheiten und der wachsenden Nachfrage nach schnellen und zugänglichen Diagnoselösungen.
Der Länderteil des Berichts enthält zudem Informationen zu einzelnen marktbeeinflussenden Faktoren und regulatorischen Veränderungen im Inland, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie die Analyse der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, die Fünf-Kräfte-Analyse nach Porter sowie Fallstudien dienen unter anderem der Prognose des Marktszenarios für einzelne Länder. Auch die Präsenz und Verfügbarkeit von Marken aus dem Nahen Osten und Afrika sowie die damit verbundenen Herausforderungen aufgrund starker oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten werden bei der Prognoseanalyse der Länderdaten berücksichtigt.
Marktanteile im Point-of-Care-Testing (POCT) im Nahen Osten und Afrika
Die Wettbewerbslandschaft des Marktes liefert detaillierte Informationen zu den einzelnen Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz im Nahen Osten und Afrika, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben genannten Datenpunkte beziehen sich ausschließlich auf die Marktausrichtung der Unternehmen.
Die Marktführer im Bereich Point-of-Care-Tests (POCT) im Nahen Osten und Afrika sind:
- F. Hoffmann-La Roche Ltd (Schweiz)
- Danaher Corporation (USA)
- Siemens Healthineers AG (Deutschland)
- BD (Becton, Dickinson and Company) (USA)
- Abbott (USA) Pfizer Inc. (USA)
- QuantuMDx Group Ltd. (Großbritannien)
- Thermo Fisher Scientific Inc. (USA)
- Nova Biomedical (USA)
- Trividia Health, Inc. (USA)
- Sienco, Inc. (USA)
- PTS Diagnostics (USA)
- Abaxis (ein Teil von Zoetis) (USA)
- Werfen (Spanien)
- Binx Health (USA)
- BIOMÉRIEUX (Frankreich)
- QIAGEN (Deutschland)
- QuidelOrtho Corporation (USA)
- Accubiotech Co., Ltd. (China)
- Sekisui Diagnostics (USA)
- Trinity Biotech (Irland)
- BD Veritor (BD) (USA)
- Hologic, Inc. (USA)
- Sysmex Corporation (Japan)
- Meridian Bioscience (USA)
Neueste Entwicklungen im Markt für Point-of-Care-Tests (POCT) im Nahen Osten und Afrika
- Im Dezember 2023 hat Roche ausgewählte Teile der innovativen Point-of-Care-Technologie von LumiraDx übernommen und damit sein Diagnostikportfolio erweitert. Diese Akquisition ermöglicht schnellere und kostengünstigere Tests für verschiedene Krankheitsbereiche. Die Integration der LumiraDx-Plattform wird den Patientenzugang zu zeitnahen und präzisen Diagnoseergebnissen in dezentralen Gesundheitseinrichtungen im Nahen Osten und in Afrika verbessern.
- Im Januar 2025 ist die Danaher Corporation eine Investitionspartnerschaft mit Innovaccer Inc. eingegangen, einem Unternehmen für KI im Gesundheitswesen. Ziel dieser Zusammenarbeit ist es, die Einführung von Präzisionsdiagnostik und wertorientierter Versorgung zu beschleunigen, indem Gesundheitsdienstleistern einheitliche Patientendaten und fortschrittliche Analysen zur Verfügung gestellt werden. So werden die Behandlungsergebnisse durch personalisierte und zeitnahe Interventionen verbessert.
- Im Februar 2025 kündigte BD die Trennung seiner Geschäftsbereiche Biosciences und Diagnostic Solutions an, um den strategischen Fokus zu stärken, das Wachstum voranzutreiben und Wert zu schöpfen. Ziel ist die Schaffung zweier unabhängiger Einheiten, die jeweils besser positioniert sind, um ihre jeweiligen Märkte zu erschließen. Diese Entscheidung unterstreicht BDs Engagement, seine Führungsrolle bei Innovationen im Gesundheitswesen zu stärken und gleichzeitig die betriebliche Effizienz für langfristigen Erfolg zu optimieren.
- Im November 2023 kooperiert Binx Health mit Fisher Healthcare, um den Vertrieb des FDA-zugelassenen binx io, einer molekularen Point-of-Care-Plattform zum Nachweis von Chlamydien und Gonorrhoe, zu erweitern. Dieses System liefert Ergebnisse in Laborqualität in etwa 30 Minuten, verbessert zeitnahe Diagnosen und ermöglicht es Ärzten, Patienten in einem einzigen Besuch zu testen und zu behandeln, was den Zugang zur Gesundheitsversorgung verbessert.
- Im April 2023 erweitert Binx Health seine Vertriebsorganisation, um der wachsenden Nachfrage nach seiner FDA-zugelassenen, CLIA-freigestellten Plattform binx io gerecht zu werden, die Chlamydien und Gonorrhoe in 30 Minuten erkennt. Diese molekulare Point-of-Care-Lösung bietet die Leistung eines zentralen Labors und trägt dem dringenden Bedarf an zugänglichen und zeitnahen STI-Tests Rechnung, wodurch die Versorgung in den USA verbessert wird.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 HEALTHCARE ECONOMY
4.3.1 HEALTHCARE EXPENDITURE
4.3.2 CAPITAL EXPENDITURE
4.3.3 CAPEX TRENDS
4.3.4 CAPEX ALLOCATION
4.3.5 FUNDING SOURCES
4.3.6 INDUSTRY BENCHMARKS
4.3.7 GDP RATIO IN OVERALL GDP
4.3.8 HEALTHCARE SYSTEM STRUCTURE
4.3.9 GOVERNMENT POLICIES
4.3.10 ECONOMIC DEVELOPMENT
4.4 REIMBURSEMENT FRAMEWORK
4.5 OPPORTUNITY MAP ANALYSIS
4.6 VALUE CHAIN ANALYSIS
4.7 MICRO AND MACRO ECONOMIC FACTORS
4.7.1 CURRENT MARKET PENETRATION
4.7.2 GROWTH PROSPECTS
4.7.3 KEY PRICING STRATEGIES
4.8 TECHNOLOGY ROADMAP: MIDDLE EAST AND AFRICA POINT OF CARE TESTING
5 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
6.1.2 RISING INCIDENCE OF SUBSTANCE ABUSE
6.1.3 INCREASED ADOPTION OF TELEMEDICINE
6.1.4 ADVANCEMENTS TECHNOLOGIES ENHANCING POC TESTING WITH BIOSENSORS AND MOBILE INTEGRATION
6.2 RESTRAINTS
6.2.1 DATA SECURITY AND PRIVACY CONCERNS
6.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
6.3 OPPORTUNITIES
6.3.1 RISING AWARENESS AND ADVOCACY FOR POINT-OF-CARE TESTING
6.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
6.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE TESTING
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS AND ACCEPTANCE
6.4.2 IMPACT OF HIGH MAINTENANCE COSTS THREATENING POINT-OF-CARE TESTING (POCT) SUSTAINABILITY IN LOW-RESOURCE SETTINGS
7 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 GLUCOSE MONITORING PRODUCTS
7.2.1 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES
7.2.1.1 Strips
7.2.1.2 Meters
7.2.1.3 Lancets and Lancing Devices
7.2.2 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS
7.3 INFECTIOUS DISEASE TESTING PRODUCTS
7.3.1 COVID-19
7.3.2 HIV TESTING PRODUCTS
7.3.2.1 Testing Reagents
7.3.2.2 Testing Equipment
7.3.3 RESPIRATORY INFECTION TESTING PRODUCTS
7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING
7.3.4.1 NAAT-Based Systems
7.3.4.2 NON–NAAT-Based Systems
7.3.5 HEPATITIS C TESTING PRODUCTS
7.3.5.1 HCV Antibody Tests
7.3.5.2 HCV Viral Load Tests
7.3.6 INFLUENZA TESTING PRODUCTS
7.3.6.1 Traditional Diagnostic Test
7.3.6.2 Molecular Diagnostic Assay
7.3.6.2.1 Rapid Influenza Diagnostic Test (RIDT)
7.3.6.2.2 Direct Fluorescent Antibody Test (DFAT)
7.3.6.2.3 Viral Culture
7.3.6.2.4 Serological Assay
7.3.6.3 RT-PCR
7.3.6.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
7.3.6.5 Nucleic Acid Sequence-Based Amplification Test (NASBAT)
7.3.6.6 Simple Amplification-Based Assay (SAMBA)
7.3.6.7 Healthcare Associated Infection (HAI) Testing
7.3.6.8 Tropical Disease Testing Products
7.3.6.9 Other Infectious Disease Testing Products
7.4 CARDIOMETABOLIC MONITORING PRODUCTS
7.4.1 CARDIAC MARKER TESTING PRODUCTS
7.4.1.1 HSTNL
7.4.1.2 BNP
7.4.1.3 D-DIMER
7.4.1.4 CK-MB
7.4.1.5 Myoglobin
7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
7.4.2.1 Blood Gas/Electrolyte Testing Consumables
7.4.2.2 Blood Gas/Electrolyte Testing Instruments
7.4.3 CARTRIDGES
7.4.4 REAGENTS
7.4.4.1 Portable
7.4.4.2 Benchtop
7.4.4.3 Combined Analyzers
7.4.4.4 Blood Gas Analyzers
7.4.4.5 Electrolyte Analyzers
7.4.4.6 Combined Analyzers
7.4.4.7 Blood Gas Analyzers
7.4.4.8 Electrolyte Analyzers
7.4.5 HBA1C TESTING PRODUCTS
7.4.5.1 HBA1C Testing Instruments
7.4.5.2 HBA1C Testing Consumables
7.4.5.3 POC Analyzer
7.4.5.4 ECG Device
7.4.5.5 Resting ECG Devices
7.4.5.6 Stress ECG Devices
7.4.5.7 Holter Monitors
7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.5.1 PREGNANCY TESTING PRODUCTS
7.5.1.1 Strips/ Dip Sticks and Cards
7.5.1.2 Mid Stream Devices
7.5.1.3 Cassettes
7.5.1.4 Digital Devices
7.5.1.5 Line-Indicator Devices
7.5.2 FERTILITY TESTING PRODUCTS
7.5.2.1 Luteinizing Hormone (LH) Urine Test
7.5.2.2 FSH Test
7.5.2.3 others
7.6 HAEMATOLOGY TESTING PRODUCTS
7.7 COAGULATION MONITORING PRODUCTS
7.7.1 ANTICOAGULATION MONITORING DEVICES
7.7.1.1 Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices
7.7.1.2 Activated Clotting Time (ACT)
7.7.1.3 Activated Partial Thromboplastin Time (APPT)
7.7.1.4 Platelet Function Monitoring Devices
7.7.1.5 Viscoelastic Coagulation Monitoring Devices
7.7.1.6 Rotational Thromboelastometry (ROTEM)
7.7.1.7 Thromboelastography (TEG)
7.7.1.8 Drug-Of-Abuse (DOA) Testing Products
7.7.2 DOA ANALYSERS
7.7.2.1 Immunoassays
7.7.2.2 Chromatographic Devices
7.7.2.3 Breath Analysers
7.7.3 RAPID TESTING DEVICES
7.7.3.1 Urine Testing Devices
7.7.3.2 Oral Fluid Testing Devices
7.7.3.4 Others
7.8 URINALYSIS TESTING PRODUCTS
7.8.1.1 POC Urine Strip Self-Testing
7.8.1.2 POC Urine Test Strip Professional Testing
7.9 CHOLESTEROL TESTING PRODUCTS
7.9.1.1 Testing Kits
7.9.1.2 Instruments
7.9.1.3 Table-Top Analyzers
7.9.1.4 Hand-Held Analyzers
7.1 TUMOR/CANCER MARKER TESTING PRODUCTS
7.11 FECAL OCCULT TESTING PRODUCTS
7.11.1.1 Guaiac FOB Stool Test
7.11.1.2 Lateral Flow Immuno-FOB Test
7.11.1.3 Immuno-FOB Agglutination Test
7.11.1.4 Immuno-FOB ELISA Test
7.12 OTHERS
8 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM
8.1 OVERVIEW
8.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS
8.3 IMMUNOASSAYS
8.4 DIPSTICKS
8.5 MOLECULAR DIAGNOSTICS
8.6 CLINICAL CHEMISTRY ASSAYS
8.7 MICROFLUIDICS
8.8 HEMATOLOGY
8.9 OTHERS
9 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BLOOD GLUCOSE
9.3 INFECTIOUS DISEASES
9.3.1 COVID-19 TESTING
9.3.2 HIV TESTING
9.3.3 HEPATITIS C TESTING
9.3.4 INFLUENZA TESTING
9.3.5 TUBERCULOSIS TESTING
9.3.6 OTHERS
9.4 VITAL SIGN MONITORING
9.5 CARDIAC MONITORING
9.6 COAGULATION
9.7 HAEMATOLOGY
9.8 NON- INVASIVE SPO2 MONITORING
9.9 BLOOD TRANSFUSION
9.1 NON- INVASIVE PCO2 MONITORING
9.11 WHOLE BLOOD ANALYSIS
9.12 OTHERS
10 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE
10.1 OVERVIEW
10.2 OTC TESTING
10.3 PRESCRIPTION-BASED TESTING
11 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
11.4 ONLINE SALES
11.5 OTHERS
12 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PRIVATE
12.2.1.1 Tier 1
12.2.1.2 Tier 2
12.2.1.3 Tier 3
12.2.2 PUBLIC
12.2.2.1 Tier 1
12.2.2.2 Tier 2
12.2.2.3 Tier 3
12.3 HOME CARE
12.4 CLINICS
12.5 LABORATORIES
12.6 DIAGNOSTIC CENTERS
12.7 PATHOLOGY LABS
12.8 AMBULATORY SURGERY CENTERS
12.9 ELDERLY CARE CENTERS
12.1 OTHERS
13 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 U.A.E.
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 ABBOTT POINT OF CARE INC(ABBOTT)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 SINOCARE.
16.2.1 COMPANY SNAPSHOT
16.2.2 COMPANY SHARE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 F. HOFFMANN-LA ROCHE LTD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 DANAHER
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 HOLOGIC, INC
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ACCUBIOTECH CO., LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ABAXIS (ABAXIS IS A PART OF ZOETIS)
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 AUTOBIO
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BD VERITOR(BD)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BINX HEALTH
16.10.1 COMPANY SNAPSHOT
16.10.2 SOLUTION PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIOMERIEUX
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BIO- RAD LABORATORIES, INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CHEMBIO DIAGNOSTICS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 EKF DIAGNOSTICS HOLDINGS PLC
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 GETEIN BIOTECH, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 LAMDAGEN CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 MERIDIAN BIOSCIENCE
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 NOVA BIOMEDICAL
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PFIZER INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 PTS DIAGNOSTICS
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 QIAGEN
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT
16.22 QUIDELORTHO CORPORATION
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 QUANTUMDX GROUP LTD.
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENT
16.24 SEKISUI DIAGNOSTICS
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT. DEVELOPMENT
16.25 SHENZHEN NEW INDUSTRY BIOMEDICAL ENGINEERING CO., LTD.
16.25.1 COMPANY SNAPSHOT
16.25.2 REVENUE ANALYSIS
16.25.3 PRODUCT PORTFOLIO
16.25.4 RECENT DEVELOPMENT
16.26 SIEMENS HEALTHINEERS AG
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENT
16.27 SIENCO, INC.
16.27.1 COMPANY SNAPSHOT
16.27.2 PRODUCT PORTFOLIO
16.27.3 RECENT UPDATES
16.28 SYSMEX CORPORATION
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENT
16.29 TRINITY BIOTECH
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PR.ODUCT PORTFOLIO
16.29.4 RECENT DEVELOPMENT
16.3 TRIVIDIA HEALTH, INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 PRODUCT PORTFOLIO
16.30.3 RECENT UPDATES
16.31 THERMO FISHER SCIENTIFIC INC.
16.31.1 COMPANY SNAPSHOT
16.31.2 REVENUE ANALYSIS
16.31.3 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT
16.32 WERFEN
16.32.1 COMPANY SNAPSHOT
16.32.2 PRODUCT PORTFOLIO
16.32.3 RECENT DEVELOPMENT
16.33 WONDFO
16.33.1 COMPANY SNAPSHOT
16.33.2 REVENUE ANALYSIS
16.33.3 PRODUCT PORTFOLIO
16.33.4 RECENT DEVELOPMENT
16.34 XIAMEN BOSON BIOTECH CO., LTD.
16.34.1 COMPANY SNAPSHOT
16.34.2 PRODUCT PORTFOLIO
16.34.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 3 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 4 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 7 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 8 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 10 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 11 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 13 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 14 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 15 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 17 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 18 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 20 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 21 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 22 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 23 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 24 MIDDLE EAST AND AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 27 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 28 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 30 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 31 MIDDLE EAST AND AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 34 MIDDLE EAST AND AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 35 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 37 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 38 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 41 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 42 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 45 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 46 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 47 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 48 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 49 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 51 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 52 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 54 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 55 MIDDLE EAST AND AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 59 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 60 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 62 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 63 MIDDLE EAST AND AFRICA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 65 MIDDLE EAST AND AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 66 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 68 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 69 MIDDLE EAST AND AFRICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSANDS)
TABLE 70 MIDDLE EAST AND AFRICA DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 73 MIDDLE EAST AND AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 74 MIDDLE EAST AND AFRICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 75 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 77 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 78 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 81 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 82 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 83 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 85 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 86 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)
TABLE 87 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 88 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 89 MIDDLE EAST AND AFRICA TUMOR/CANCER MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 90 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 91 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)
TABLE 93 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 94 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 95 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 96 MIDDLE EAST AND AFRICA LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 97 MIDDLE EAST AND AFRICA IMMUNOASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 98 MIDDLE EAST AND AFRICA DIPSTICKS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 99 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 100 MIDDLE EAST AND AFRICA CLINICAL CHEMISTRY ASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 101 MIDDLE EAST AND AFRICA MICROFLUIDICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 102 MIDDLE EAST AND AFRICA HEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 103 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 104 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 105 MIDDLE EAST AND AFRICA BLOOD GLUCOSE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 106 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 107 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 MIDDLE EAST AND AFRICA VITAL SIGN MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 109 MIDDLE EAST AND AFRICA CARDIAC MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 110 MIDDLE EAST AND AFRICA COAGULATION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 111 MIDDLE EAST AND AFRICA HAEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 112 MIDDLE EAST AND AFRICA NON- INVASIVE SPO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 113 MIDDLE EAST AND AFRICA BLOOD TRANSFUSION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 114 MIDDLE EAST AND AFRICA NON- INVASIVE PCO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 115 MIDDLE EAST AND AFRICA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 116 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 117 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSANDS)
TABLE 118 MIDDLE EAST AND AFRICA OTC TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 119 MIDDLE EAST AND AFRICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)
TABLE 120 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD MILLION)
TABLE 121 MIDDLE EAST AND AFRICA DIRECT TENDER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 122 MIDDLE EAST AND AFRICA RETAIL SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 123 MIDDLE EAST AND AFRICA ONLINE SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 124 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)
TABLE 125 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 126 MIDDLE EAST AND AFRICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)
TABLE 127 MIDDLE EAST AND AFRICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSANDS)
TABLE 128 MIDDLE EAST AND AFRICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)
TABLE 129 MIDDLE EAST AND AFRICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)
TABLE 130 MIDDLE EAST AND AFRICA HOME CARE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 131 MIDDLE EAST AND AFRICA CLINICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 132 MIDDLE EAST AND AFRICA LABORATORIES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 133 MIDDLE EAST AND AFRICA DIAGNOSTIC CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 134 MIDDLE EAST AND AFRICA PATHOLOGY LABS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 135 MIDDLE EAST AND AFRICA AMBULATORY SURGERY CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 136 MIDDLE EAST AND AFRICA ELDERLY CARE CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 137 MIDDLE EAST AND AFRICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 138 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 139 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 140 MIDDLE EAST AND AFRICA
TABLE 141 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 143 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 144 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 146 MIDDLE EAST AND AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 147 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 149 MIDDLE EAST AND AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 150 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 152 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 153 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 155 MIDDLE EAST AND AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 156 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 158 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 159 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 161 MIDDLE EAST AND AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 162 MIDDLE EAST AND AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 165 MIDDLE EAST AND AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 166 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 167 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 168 MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 169 MIDDLE EAST AND AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 MIDDLE EAST AND AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 171 MIDDLE EAST AND AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 172 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 174 MIDDLE EAST AND AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 175 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 176 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 178 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 179 MIDDLE EAST AND AFRICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 182 MIDDLE EAST AND AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 183 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 185 MIDDLE EAST AND AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 186 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 187 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 188 MIDDLE EAST AND AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 189 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 191 MIDDLE EAST AND AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 192 MIDDLE EAST AND AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 195 MIDDLE EAST AND AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 196 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 198 MIDDLE EAST AND AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 199 MIDDLE EAST AND AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 202 MIDDLE EAST AND AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 203 MIDDLE EAST AND AFRICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 204 MIDDLE EAST AND AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 MIDDLE EAST AND AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 206 MIDDLE EAST AND AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 207 MIDDLE EAST AND AFRICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 208 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 209 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 210 MIDDLE EAST AND AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 211 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 213 MIDDLE EAST AND AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 214 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 215 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 216 MIDDLE EAST AND AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 217 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 218 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 219 MIDDLE EAST AND AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 220 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 222 MIDDLE EAST AND AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 223 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 224 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 225 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 227 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 228 MIDDLE EAST AND AFRICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 MIDDLE EAST AND AFRICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 230 MIDDLE EAST AND AFRICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 231 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 232 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 234 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 235 SAUDI ARABIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 SAUDI ARABIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 237 SAUDI ARABIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 238 SAUDI ARABIA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 SAUDI ARABIA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 240 SAUDI ARABIA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 241 SAUDI ARABIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 SAUDI ARABIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 243 SAUDI ARABIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 244 SAUDI ARABIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 SAUDI ARABIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 246 SAUDI ARABIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 247 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 249 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 250 SAUDI ARABIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 251 SAUDI ARABIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 252 SAUDI ARABIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 253 SAUDI ARABIA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 SAUDI ARABIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 SAUDI ARABIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 256 SAUDI ARABIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 257 SAUDI ARABIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 SAUDI ARABIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 259 SAUDI ARABIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 260 SAUDI ARABIA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 261 SAUDI ARABIA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 262 SAUDI ARABIA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 263 SAUDI ARABIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 264 SAUDI ARABIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 265 SAUDI ARABIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 266 SAUDI ARABIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 267 SAUDI ARABIA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 268 SAUDI ARABIA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 269 SAUDI ARABIA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 270 SAUDI ARABIA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 271 SAUDI ARABIA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 272 SAUDI ARABIA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 273 SAUDI ARABIA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 274 SAUDI ARABIA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 275 SAUDI ARABIA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 276 SAUDI ARABIA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 277 SAUDI ARABIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 278 SAUDI ARABIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 279 SAUDI ARABIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 280 SAUDI ARABIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 281 SAUDI ARABIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 282 SAUDI ARABIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 283 SAUDI ARABIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 284 SAUDI ARABIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 285 SAUDI ARABIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 286 SAUDI ARABIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 287 SAUDI ARABIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 288 SAUDI ARABIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 289 SAUDI ARABIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 290 SAUDI ARABIA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 291 SAUDI ARABIA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 292 SAUDI ARABIA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 293 SAUDI ARABIA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 294 SAUDI ARABIA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 295 SAUDI ARABIA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 296 SAUDI ARABIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 297 SAUDI ARABIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 298 SAUDI ARABIA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 299 SAUDI ARABIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 300 SAUDI ARABIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 301 SAUDI ARABIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 302 SAUDI ARABIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 303 SAUDI ARABIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 304 SAUDI ARABIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 305 SAUDI ARABIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 306 SAUDI ARABIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 307 SAUDI ARABIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 308 SAUDI ARABIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 309 SAUDI ARABIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 310 SAUDI ARABIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 311 SAUDI ARABIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 312 SAUDI ARABIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 313 SAUDI ARABIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 314 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 315 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 316 SAUDI ARABIA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 317 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 318 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 319 SAUDI ARABIA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 320 SAUDI ARABIA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 321 SAUDI ARABIA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 322 SAUDI ARABIA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 323 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 324 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 325 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 326 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 327 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 328 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 329 SOUTH AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 330 SOUTH AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 331 SOUTH AFRICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 332 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 333 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 334 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 335 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 336 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 337 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 338 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 339 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 340 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 341 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 342 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 343 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 344 SOUTH AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 345 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 346 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 347 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 348 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 349 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 350 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 351 SOUTH AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 352 SOUTH AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 353 SOUTH AFRICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 354 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 355 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 356 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 357 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 358 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 359 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 360 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 361 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 362 SOUTH AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 363 SOUTH AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 364 SOUTH AFRICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 365 SOUTH AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 366 SOUTH AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 367 SOUTH AFRICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 368 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 369 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 370 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 371 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 372 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 373 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 374 SOUTH AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 375 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 376 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 377 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 378 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 379 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 380 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 381 SOUTH AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 382 SOUTH AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 383 SOUTH AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 384 SOUTH AFRICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 385 SOUTH AFRICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 386 SOUTH AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 387 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 388 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 389 SOUTH AFRICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 390 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 391 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 392 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 393 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 394 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 395 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 396 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 397 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 398 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 399 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 400 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 401 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 402 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 403 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 404 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 405 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 406 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 407 SOUTH AFRICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 408 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 409 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 410 SOUTH AFRICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 411 SOUTH AFRICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 412 SOUTH AFRICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 413 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 414 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 415 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 416 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 417 U.A.E GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 418 U.A.E GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 419 U.A.E GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 420 U.A.E SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 421 U.A.E SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 422 U.A.E SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 423 U.A.E INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 424 U.A.E INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 425 U.A.E INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 426 U.A.E HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 427 U.A.E HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 428 U.A.E HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 429 U.A.E SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 430 U.A.E SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 431 U.A.E SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 432 U.A.E HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 433 U.A.E HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 434 U.A.E HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 435 U.A.E INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 436 U.A.E TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 437 U.A.E TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 438 U.A.E TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 439 U.A.E MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 440 U.A.E MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 441 U.A.E MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 442 U.A.E CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 443 U.A.E POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 444 U.A.E POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 445 U.A.E CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 446 U.A.E CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 447 U.A.E CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 448 U.A.E BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 449 U.A.E BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 450 U.A.E BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 451 U.A.E BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 452 U.A.E BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 453 U.A.E PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 454 U.A.E PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 455 U.A.E PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 456 U.A.E BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 457 U.A.E BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 458 U.A.E BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 459 U.A.E HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 460 U.A.E HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 461 U.A.E HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 462 U.A.E ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 463 U.A.E ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 464 U.A.E ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 465 U.A.E PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 466 U.A.E PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 467 U.A.E PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 468 U.A.E PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 469 U.A.E FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 470 U.A.E FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 471 U.A.E FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 472 U.A.E COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 473 U.A.E ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 474 U.A.E ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 475 U.A.E ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 476 U.A.E VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 477 U.A.E DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 478 U.A.E DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 479 U.A.E DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 480 U.A.E DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 481 U.A.E RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 482 U.A.E RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 483 U.A.E RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 484 U.A.E URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 485 U.A.E URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 486 U.A.E URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 487 U.A.E CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 488 U.A.E CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 489 U.A.E CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 490 U.A.E INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 491 U.A.E INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 492 U.A.E INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 493 U.A.E FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 494 U.A.E FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 495 U.A.E FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 496 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 497 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 498 U.A.E INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 499 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 500 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 501 U.A.E HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 502 U.A.E PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 503 U.A.E PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 504 U.A.E POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 505 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 506 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 507 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 508 ISRAEL GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 509 ISRAEL GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 510 ISRAEL GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 511 ISRAEL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 512 ISRAEL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 513 ISRAEL SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 514 ISRAEL INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 515 ISRAEL INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 516 ISRAEL INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 517 ISRAEL HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 518 ISRAEL HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 519 ISRAEL HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 520 ISRAEL SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 521 ISRAEL SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 522 ISRAEL SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 523 ISRAEL HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 524 ISRAEL HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 525 ISRAEL HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 526 ISRAEL INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 527 ISRAEL TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 528 ISRAEL TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 529 ISRAEL TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 530 ISRAEL MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 531 ISRAEL MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 532 ISRAEL MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 533 ISRAEL CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 534 ISRAEL POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 535 ISRAEL POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 536 ISRAEL CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 537 ISRAEL CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 538 ISRAEL CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 539 ISRAEL BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 540 ISRAEL BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 541 ISRAEL BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 542 ISRAEL BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 543 ISRAEL BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 544 ISRAEL PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 545 ISRAEL PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 546 ISRAEL PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 547 ISRAEL BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 548 ISRAEL BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 549 ISRAEL BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 550 ISRAEL HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 551 ISRAEL HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 552 ISRAEL HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 553 ISRAEL ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 554 ISRAEL ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 555 ISRAEL ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 556 ISRAEL PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 557 ISRAEL PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 558 ISRAEL PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 559 ISRAEL PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 560 ISRAEL FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 561 ISRAEL FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 562 ISRAEL FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 563 ISRAEL COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 564 ISRAEL ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 565 ISRAEL ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 566 ISRAEL ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 567 ISRAEL VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 568 ISRAEL DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 569 ISRAEL DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 570 ISRAEL DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 571 ISRAEL DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 572 ISRAEL RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 573 ISRAEL RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 574 ISRAEL RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 575 ISRAEL URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 576 ISRAEL URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 577 ISRAEL URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 578 ISRAEL CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 579 ISRAEL CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 580 ISRAEL CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 581 ISRAEL INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 582 ISRAEL INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 583 ISRAEL INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 584 ISRAEL FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 585 ISRAEL FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 586 ISRAEL FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 587 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 588 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 589 ISRAEL INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 590 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 591 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 592 ISRAEL HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 593 ISRAEL PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 594 ISRAEL PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 595 ISRAEL POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 596 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 597 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 598 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 599 KUWAIT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 600 KUWAIT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 601 KUWAIT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 602 KUWAIT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 603 KUWAIT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 604 KUWAIT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 605 KUWAIT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 606 KUWAIT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 607 KUWAIT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 608 KUWAIT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 609 KUWAIT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 610 KUWAIT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 611 KUWAIT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 612 KUWAIT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 613 KUWAIT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 614 KUWAIT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 615 KUWAIT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 616 KUWAIT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 617 KUWAIT INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 618 KUWAIT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 619 KUWAIT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 620 KUWAIT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 621 KUWAIT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 622 KUWAIT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 623 KUWAIT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 624 KUWAIT CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 625 KUWAIT POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 626 KUWAIT POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 627 KUWAIT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 628 KUWAIT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 629 KUWAIT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 630 KUWAIT BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 631 KUWAIT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 632 KUWAIT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 633 KUWAIT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 634 KUWAIT BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 635 KUWAIT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 636 KUWAIT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 637 KUWAIT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 638 KUWAIT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 639 KUWAIT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 640 KUWAIT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 641 KUWAIT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 642 KUWAIT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 643 KUWAIT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 644 KUWAIT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 645 KUWAIT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 646 KUWAIT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 647 KUWAIT PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 648 KUWAIT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 649 KUWAIT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 650 KUWAIT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 651 KUWAIT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 652 KUWAIT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 653 KUWAIT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 654 KUWAIT COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 655 KUWAIT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 656 KUWAIT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 657 KUWAIT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 658 KUWAIT VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 659 KUWAIT DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 660 KUWAIT DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 661 KUWAIT DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 662 KUWAIT DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 663 KUWAIT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 664 KUWAIT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 665 KUWAIT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 666 KUWAIT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 667 KUWAIT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 668 KUWAIT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 669 KUWAIT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 670 KUWAIT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 671 KUWAIT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 672 KUWAIT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 673 KUWAIT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 674 KUWAIT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 675 KUWAIT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 676 KUWAIT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 677 KUWAIT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 678 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 679 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 680 KUWAIT INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 681 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 682 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 683 KUWAIT HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 684 KUWAIT PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 685 KUWAIT PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 686 KUWAIT POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 687 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 688 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 689 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 690 EGYPT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 691 EGYPT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 692 EGYPT GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 693 EGYPT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 694 EGYPT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 695 EGYPT SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 696 EGYPT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 697 EGYPT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 698 EGYPT INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 699 EGYPT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 700 EGYPT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 701 EGYPT HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 702 EGYPT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 703 EGYPT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 704 EGYPT SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 705 EGYPT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 706 EGYPT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 707 EGYPT HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 708 EGYPT INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 709 EGYPT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 710 EGYPT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 711 EGYPT TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 712 EGYPT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 713 EGYPT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 714 EGYPT MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 715 EGYPT CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 716 EGYPT POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 717 EGYPT POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 718 EGYPT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 719 EGYPT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 720 EGYPT CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 721 EGYPT BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 722 EGYPT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 723 EGYPT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 724 EGYPT BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 725 EGYPT BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 726 EGYPT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 727 EGYPT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 728 EGYPT PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 729 EGYPT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 730 EGYPT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 731 EGYPT BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 732 EGYPT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 733 EGYPT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 734 EGYPT HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 735 EGYPT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 736 EGYPT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 737 EGYPT ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 738 EGYPT PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 739 EGYPT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 740 EGYPT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 741 EGYPT PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 742 EGYPT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 743 EGYPT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 744 EGYPT FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 745 EGYPT COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 746 EGYPT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 747 EGYPT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 748 EGYPT ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 749 EGYPT VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)
TABLE 750 EGYPT DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 751 EGYPT DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 752 EGYPT DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 753 EGYPT DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 754 EGYPT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 755 EGYPT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 756 EGYPT RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 757 EGYPT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 758 EGYPT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 759 EGYPT URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 760 EGYPT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 761 EGYPT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 762 EGYPT CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 763 EGYPT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 764 EGYPT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 765 EGYPT INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 766 EGYPT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 767 EGYPT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 768 EGYPT FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 769 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)
TABLE 770 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 771 EGYPT INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 772 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)
TABLE 773 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 774 EGYPT HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 775 EGYPT PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 776 EGYPT PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)
TABLE 777 EGYPT POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 778 REST OF MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 779 REST OF MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 780 REST OF MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)
Abbildungsverzeichnis
FIGURE 1 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES IS EXPECTED TO DRIVE THE GROWTH OF MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET FROM 2026 TO 2033
FIGURE 14 THE GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET IN 2026 - 2032
FIGURE 15 DRCO ANALYSIS
FIGURE 16 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2025
FIGURE 17 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2026-2033 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2026-2033)
FIGURE 19 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2025
FIGURE 21 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2026 TO 2033 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, CAGR (2026- 2033)
FIGURE 23 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2025
FIGURE 25 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2026 TO 2033 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2026- 2033)
FIGURE 27 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2025
FIGURE 29 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2026 TO 2033 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2026- 2033)
FIGURE 31 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 33 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2026 TO 2033 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026- 2033)
FIGURE 35 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2025
FIGURE 37 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2026 TO 2033 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2026- 2033)
FIGURE 39 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT
FIGURE 41 MIDDLE EAST AND AFRICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY SHARE 2025 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
